Subscribe to RSS
DOI: 10.1055/s-0038-1653881
KRDS, a Peptide Derived from Human Lactotransferrin, Inhibits Thrombin-Induced Thromboxane Synthesis by a Cyclooxygenase-Independent Mechanism
Publication History
Received 22 August 1994
Accepted after resubmission 24 January 1995
Publication Date:
09 July 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199505/lookinside/thumbnails/10-1055-s-0038-1653881-1.jpg)
Summary
KRDS, a tetrapeptide from human lactotransferrin, inhibits thrombin-induced platelet aggregation, secretion and thromboxane (TX) synthesis without interfering with phospholipase C (PLC) β activation, since in previous work we have shown that Ca2+ mobilization and phosphorylation of the myosin light chain kinase (20 kDa) and pleckstrin (47 kDa) were normal. However, the inhibition of arachido- nic acid-induced aggregation in the presence of KRDS is accompanied by normal TX synthesis suggesting that it does not interfere with the cyclooxygenase activity. To elucidate further the mechanisms of action of this peptide we tested its effect on U46619-induced platelet activation. KRDS inhibits U46619-induced platelet aggregation time- and dose-dependently without inhibiting the phosphorylation of pleckstrin. This suggests that the PLC pathway is not affected and that the inhibitory effect of KRDS is not due to an uncoupling of TXA2 from its receptor. In addition to the PLC pathway, protein tyrosine kinases play a major role in platelet signal transduction mechanisms. At least 7 tyrosine-phosphorylated proteins are detected upon stimulation of platelets by thrombin. KRDS strongly inhibits the tyrosine- phosphorylated substrates, in particular two 100-105 kDa substrates which are related to GP Ilb/IIIa activation and platelet aggregation. The absence of TX synthesis observed in the presence of KRDS could be due to the inactivation of cPLA2 since the latter needs tyrosine phosphorylation to be activated, thus explaining the inhibitory action of KRDS on platelet functions.
-
References
- 1 Jolles P. Structural aspects of the milk clotting process. Comparative features with the blood clotting process Mol Cell Biochem 1975; 7: 73-85
- 2 Jolies P, Henschen A. Comparison between the clotting of blood and milk. TIBS 1982; 7: 325-328
- 3 Jolies P, Lévy-Toledano S, Fiat AM, Soria C, Guillessen D, Thomaidis A, Dunn FW, Caen JP. Analogy between fibrinogen and casein Effect of an undecapeptide isolated from κ-casein on platelet function. Eur J Biochem 1986; 158: 379-382
- 4 Drouet L, Bal ditSollier, Cisse M, Pignaud G, Mazoyer E, Fiat AM, Jolies P, Caen JP. The antithrombotic effect of KRDS, a lactotransferrin peptide compared with RGDS. Nouv Rev Fr Hematol 1990; 32: 59-62
- 5 Mazoyer E, Lévy-Toledano S, Rendu F, Hermant L, Lu H, Fiat AM, Jolies P, Caen JP. KRDS, a new peptide derived from human lactotransferrin inhibits platelet aggregation and release reaction. Eur J Biochem 1990; 194: 43-49
- 6 Golden A, Nemeth SP, Brugge JS. Blood platelets express high levels of pp60 csrc-specific tyrosine kinase activity. Proc Natl Acad Sci USA 1986; 83: 852-858
- 7 Lévy-Toledano S, Maclouf J, Bryon P, Savariau E, Hardisty RM, Caen JP. Human platelet activation in the absence of aggregation: a calcium- dependent phenomenon independent of thromboxane formation. Blood 1982; 59: 1078-1083
- 8 Bom GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
- 9 Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholinesterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-1173
- 10 Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-92
- 11 Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2receptor. Nature 1991; 349: 617-620
- 12 Bachelot C, Cano E, Grelac F, Saleum S, Lévy-Toledano S, Rendu F. Functional implications of tyrosine protein phosphorylation in platelets. Biochem J 1992; 284: 923-928
- 13 Golden A, Brugge JS. Thrombin treatment induces rapid changes in tyrosine phosphorylation in platelets. Proc Natl Acad Sci USA 1989; 86: 901-906
- 14 Kramer RM, Roberts EF, Manetta JV, Hyslop PA, Jakubovski JA. Thrombin-induced phosphorylation and activation of Ca2+-sensitive cytosolic phospholipase A2in human platelets. J Biol Chem 1993; 268: 26796-26804
- 15 Lin LL, Wartman M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993; 72: 269-273
- 16 Leveugle B, Mazurier J, Legrand D, Mazurier C, Montreuil J, Spik G. Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. EurJ Biochem 1993; 213: 1205-1211
- 17 Mazurier J, Legrand D, Hu WL, Montreuil J, Spik G. Expression of human lactotransferrin receptors in phytohemagglutinin-stimulated human peripheral blood lymphocytes. Eur J Biochem 1989; 179: 481-487